Bio-Rad Laboratories Class A
484 hedge funds and large institutions have $8.13B invested in Bio-Rad Laboratories Class A in 2022 Q3 according to their latest regulatory filings, with 60 funds opening new positions, 191 increasing their positions, 147 reducing their positions, and 71 closing their positions.
30% more repeat investments, than reductions
Existing positions increased: 191 | Existing positions reduced: 147
2.29% more ownership
Funds ownership: 76.81% → 79.1% (+2.3%)
3% less funds holding
Funds holding: 500 → 484 (-16)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
14% less capital invested
Capital invested by funds: $9.46B → $8.13B (-$1.33B)
15% less first-time investments, than exits
New positions opened: 60 | Existing positions closed: 71
18% less call options, than puts
Call options by funds: $84.5M | Put options by funds: $103M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Veritas Asset Management
London,
United Kingdom
|
+$115M |
| 2 |
Brown Advisory
Baltimore,
Maryland
|
+$96.7M |
| 3 |
Amundi
Paris,
France
|
+$72.8M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$72.2M |
| 5 |
HRCM
Hawk Ridge Capital Management
Los Angeles,
California
|
+$49.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
-$66.2M |
| 2 |
AssetMark Inc
Concord,
California
|
-$56.5M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$56.1M |
| 4 |
Renaissance Technologies
New York
|
-$45.8M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
-$43.2M |
BIO Hedge Fund Activity: Q3 2022 in Review
484 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class A (BIO) for Q3 2022, worth a combined $8.13B — down 14% from $9.46B a quarter earlier.
Sellers outnumbered buyers: 71 funds closed out of BIO and 60 opened new positions — a net loss of 11 holders — while 147 trimmed existing stakes and 191 added.
The largest buyer was Veritas Asset Management, adding an estimated $115M. The largest seller was Schonfeld Strategic Advisors, cutting an estimated $66.2M.
- 484 institutional investors held Bio-Rad Laboratories Class A (BIO) as of Q3 2022, down from 500 in Q2 2022.
- Funds reported $8.13B of Bio-Rad Laboratories Class A stock for Q3 2022, down 14% quarter-over-quarter.
- 60 funds opened new Bio-Rad Laboratories Class A positions in Q3 2022 and 71 closed out, a net change of -11 holders.
- The largest Bio-Rad Laboratories Class A buyer in Q3 2022 was Veritas Asset Management, an estimated $115M added.
- The largest Bio-Rad Laboratories Class A seller in Q3 2022 was Schonfeld Strategic Advisors, an estimated $66.2M sold.
Based on aggregated 13F filings for Q3 2022.